Cargando…
Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy
BACKGROUND: Previous studies have revealed that nearly 15–20% of selected high-risk T1–2N0 breast cancers developed LRR after mastectomy. This study is aim to indentify the risk factors of locoregional recurrence (LRR) in patients with pathologic T1–2N0 breast cancer after mastectomy in a real-world...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685539/ https://www.ncbi.nlm.nih.gov/pubmed/33228588 http://dx.doi.org/10.1186/s12885-020-07594-7 |
_version_ | 1783613200149774336 |
---|---|
author | Wang, Jianyang Tang, Yu Jing, Hao Sun, Guangyi Jin, Jing Liu, Yueping Song, Yongwen Wang, Weihu Fang, Hui Chen, Bo Qi, Shunan Ren, Hua Li, Ning Tang, Yuan Lu, Ningning Yang, Yong Yu, Zihao Wang, Shulian Li, Yexiong |
author_facet | Wang, Jianyang Tang, Yu Jing, Hao Sun, Guangyi Jin, Jing Liu, Yueping Song, Yongwen Wang, Weihu Fang, Hui Chen, Bo Qi, Shunan Ren, Hua Li, Ning Tang, Yuan Lu, Ningning Yang, Yong Yu, Zihao Wang, Shulian Li, Yexiong |
author_sort | Wang, Jianyang |
collection | PubMed |
description | BACKGROUND: Previous studies have revealed that nearly 15–20% of selected high-risk T1–2N0 breast cancers developed LRR after mastectomy. This study is aim to indentify the risk factors of locoregional recurrence (LRR) in patients with pathologic T1–2N0 breast cancer after mastectomy in a real-world and distinguish individuals who warrant postmastectomy radiotherapy (PMRT). METHODS: Female patients treated from 1999 to 2014 in National Cancer Center of China were retrospectively reviewed. A competing risk model was developed to estimate the cumulative incidence of LRR with death treated as a competing event. RESULTS: A total of 4841 patients were eligible. All underwent mastectomy plus axillary nodes dissection or sentinel node biopsy without PMRT. With a median follow-up of 56.4 months (range, 1–222 months), the 5-year LRR rate was 3.9%.Besides treatment era, age ≤ 40 years old (p < 0.001, hazard ratio [HR] = 2.262), tumor located in inner quadrant (p < 0.001, HR = 2.236), T2 stage (p = 0.020, HR = 1.419), and negative expressions of estrogen receptor (ER) and progesterone receptor (PR) (p = 0.032, HR = 1.485), were patients-related independent risk factors for LRR. The 5-year LRR rates were 1.7, 3.5, and 15.0% for patients with zero, 1–2, and 3–4 risk factors (p < 0.001). CONCLUSIONS: Risk Stratification based on age, T stage, ER/PR status and tumor location can stratify patients with pT1–2 N0 breast cancer into subgroups with different risk of LRR. PMRT might be suggested for patients with 3–4 risk factors. |
format | Online Article Text |
id | pubmed-7685539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-76855392020-11-25 Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy Wang, Jianyang Tang, Yu Jing, Hao Sun, Guangyi Jin, Jing Liu, Yueping Song, Yongwen Wang, Weihu Fang, Hui Chen, Bo Qi, Shunan Ren, Hua Li, Ning Tang, Yuan Lu, Ningning Yang, Yong Yu, Zihao Wang, Shulian Li, Yexiong BMC Cancer Research Article BACKGROUND: Previous studies have revealed that nearly 15–20% of selected high-risk T1–2N0 breast cancers developed LRR after mastectomy. This study is aim to indentify the risk factors of locoregional recurrence (LRR) in patients with pathologic T1–2N0 breast cancer after mastectomy in a real-world and distinguish individuals who warrant postmastectomy radiotherapy (PMRT). METHODS: Female patients treated from 1999 to 2014 in National Cancer Center of China were retrospectively reviewed. A competing risk model was developed to estimate the cumulative incidence of LRR with death treated as a competing event. RESULTS: A total of 4841 patients were eligible. All underwent mastectomy plus axillary nodes dissection or sentinel node biopsy without PMRT. With a median follow-up of 56.4 months (range, 1–222 months), the 5-year LRR rate was 3.9%.Besides treatment era, age ≤ 40 years old (p < 0.001, hazard ratio [HR] = 2.262), tumor located in inner quadrant (p < 0.001, HR = 2.236), T2 stage (p = 0.020, HR = 1.419), and negative expressions of estrogen receptor (ER) and progesterone receptor (PR) (p = 0.032, HR = 1.485), were patients-related independent risk factors for LRR. The 5-year LRR rates were 1.7, 3.5, and 15.0% for patients with zero, 1–2, and 3–4 risk factors (p < 0.001). CONCLUSIONS: Risk Stratification based on age, T stage, ER/PR status and tumor location can stratify patients with pT1–2 N0 breast cancer into subgroups with different risk of LRR. PMRT might be suggested for patients with 3–4 risk factors. BioMed Central 2020-11-23 /pmc/articles/PMC7685539/ /pubmed/33228588 http://dx.doi.org/10.1186/s12885-020-07594-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Wang, Jianyang Tang, Yu Jing, Hao Sun, Guangyi Jin, Jing Liu, Yueping Song, Yongwen Wang, Weihu Fang, Hui Chen, Bo Qi, Shunan Ren, Hua Li, Ning Tang, Yuan Lu, Ningning Yang, Yong Yu, Zihao Wang, Shulian Li, Yexiong Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy |
title | Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy |
title_full | Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy |
title_fullStr | Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy |
title_full_unstemmed | Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy |
title_short | Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy |
title_sort | risk stratification for prediction of locoregional recurrence in patients with pathologic t1–2n0 breast cancer after mastectomy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685539/ https://www.ncbi.nlm.nih.gov/pubmed/33228588 http://dx.doi.org/10.1186/s12885-020-07594-7 |
work_keys_str_mv | AT wangjianyang riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT tangyu riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT jinghao riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT sunguangyi riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT jinjing riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT liuyueping riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT songyongwen riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT wangweihu riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT fanghui riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT chenbo riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT qishunan riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT renhua riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT lining riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT tangyuan riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT luningning riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT yangyong riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT yuzihao riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT wangshulian riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy AT liyexiong riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy |